Full Fed. Circ. Told Newer Amgen Drug Patent Was 'Trivial'
An Indian drugmaker wants the full Federal Circuit to take another look at a ruling that dashed its efforts to break Amgen's grip on its anti-cancer drug Kyprolis, arguing that a...To view the full article, register now.
Already a subscriber? Click here to view full article